Par Pharmaceutical to sell Tranylcypromine sulfate tablets for treatment of depression

By Elaine Rigoli

Tampa, Fla., June 30 - Par Pharmaceutical Cos., Inc. announced that its wholly owned subsidiary, Kali Laboratories, Inc., has received final approval from the Food and Drug Administration for its abbreviated New Drug Application for tranylcypromine sulfate tablets, 10 mg.

Tranylcypromine is the generic version of GlaxoSmithKline's Parnate and is used for the treatment of depression.

Annual U.S. sales of Parnate exceed $6 million, according to a news release.

Par said it will begin shipping the product immediately.

Par is a pharmaceutical company based in Woodcliff Lake, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.